Clinical Trials Logo

Clinical Trial Summary

This is a three-part open label phase 1 study designed to determine the safety profile, MTD, PK and tumor and biomarker response after IT or IV administration of a single dose of VSV-IFNβ-NIS, or combined IT followed by IV VSV-IFNβ-NIS, with or without IV avelumab every two weeks, in patients with refractory advanced/metastatic solid tumors.


Clinical Trial Description

The study consists of three parts: a single ascending dose escalation of IT VSV-IFNβ-NIS monotherapy, a monotherapy IV regimen selection phase and an expansion phase, designed to explore the safety and efficacy of the chosen monotherapy regimen alone or in combination with avelumab in patients with metastatic colorectal cancer. Monotherapy will also be explored in patients with pheochromocytoma and NET. Patients are required to have at least 1 measurable lesion per RECIST 1.1, and in the IT-containing arms this lesion should be amenable for a one-time IT injection of VSV-IFNβ-NIS. At least one patient per IT cohort is required to have at least 2 measurable lesions per RECIST 1.1, one for a one-time IT injection of VSV-IFNβ-NIS and one to be used as a control. Priority enrollment in the IT-containing arms will be granted to patients with 2 measurable lesions per RECIST 1.1. At least one patient per dose level should have metastatic colorectal cancer. In order to fulfil these requirements, at least 3 or 4 patients will be required per escalation dose cohort. Other tumor types of particular interest based on prior experience with VSV or oncolytic viruses include malignant melanoma and endometrial cancer. When more than one cohort is open simultaneously, slot assignment will be determined by the sponsor in consultation with the PIs. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02923466
Study type Interventional
Source Vyriad, Inc.
Contact
Status Completed
Phase Phase 1
Start date April 17, 2017
Completion date April 22, 2022

See also
  Status Clinical Trial Phase
Completed NCT01721148 - A Phase I Multiple Ascending Dose Study of ASLAN002 in Subjects With Advanced or Metastatic Solid Tumours Phase 1
Completed NCT00551096 - Gemcitabine/Capecitabine/ZD6474 in Advanced Solid Tumors Phase 1
Completed NCT01023737 - Hydroxychloroquine + Vorinostat in Advanced Solid Tumors Phase 1
Completed NCT01435096 - BN80927 in Patients With Advanced Malignant Solid Tumors Phase 1
Completed NCT01951846 - To Determine the Maximum Tolerated Dose (MTD) of BIBF 1120 in Patients With Solid Tumours Phase 1
Completed NCT01325558 - A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors Phase 1
Completed NCT01554371 - Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies Phase 1/Phase 2
Recruiting NCT01309490 - Phase I/II Study of Ribavirin Given as Monotherapy in Solid Tumour Cancer Patients Phase 1/Phase 2
Recruiting NCT01286896 - Use of Individual Pharmacokinetically (PK)-Guided Sunitinib Dosing: A Feasibility Study in Patients With Advanced Solid Tumors Phase 1
Completed NCT00635791 - Phase I Study of Vorinostat and Sorafenib in Advanced Cancer Phase 1
Completed NCT01376505 - Vaccine Therapy in Treating Patients With Metastatic Solid Tumors Phase 1
Completed NCT00388427 - Safety Study Of Cetuximab Plus Dasatinib (BMS-354825) in Treating Advanced Solid Malignancies Phase 1
Completed NCT01611857 - Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach Phase 1/Phase 2
Completed NCT02853903 - Comparison of Autogenic and Allogenic NK Immunotherapy on the Outcome of Recurrent Solid Tumors Phase 2
Completed NCT02843204 - Combination of Anti-PD-1 and NK Immunotherapy for Recurrent Solid Tumors Phase 1/Phase 2
Completed NCT01618136 - An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Terminated NCT00801151 - Vorinostat in Combination With Vinorelbine in Patients With Advanced Cancer Phase 1
Completed NCT02786628 - Assessing Physical Fitness in Cancer Patients With Cardiopulmonary Exercise Testing and Wearable Data Generation
Completed NCT01184807 - Phase 1, Dose-escalation Trial of OPB-51602 in Patients With Advanced Solid Tumors Phase 1
Completed NCT00969410 - A Pharmacodynamic Study of AV-299 (Formerly SCH 900105) in Subjects With Advanced Solid Tumors Who Have Liver Metastases Phase 1